343 related articles for article (PubMed ID: 25823662)
41. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
42. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
43. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
44. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
45. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
46. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
47. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
48. Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.
Hsu PC; Chiu LC; Li SH; Chen CH; Wang CL; Kao KC; Chang JW; Wang CW; Yu CT; Chung FT; Yang CT; Liu CY
Biomed J; 2016 Apr; 39(2):121-9. PubMed ID: 27372167
[TBL] [Abstract][Full Text] [Related]
49. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
[TBL] [Abstract][Full Text] [Related]
50. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
[TBL] [Abstract][Full Text] [Related]
51. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
52. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.
Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH
Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202
[TBL] [Abstract][Full Text] [Related]
53. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
54. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J
J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608
[TBL] [Abstract][Full Text] [Related]
55. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.
Zhu X; Bai Q; Lu Y; Qi P; Ding J; Wang J; Zhou X
Target Oncol; 2017 Feb; 12(1):81-88. PubMed ID: 27538584
[TBL] [Abstract][Full Text] [Related]
56. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
57. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
58. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
Chen ZY; Zhong WZ; Zhang XC; Su J; Yang XN; Chen ZH; Yang JJ; Zhou Q; Yan HH; An SJ; Chen HJ; Jiang BY; Mok TS; Wu YL
Oncologist; 2012; 17(7):978-85. PubMed ID: 22673630
[TBL] [Abstract][Full Text] [Related]
59. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
[TBL] [Abstract][Full Text] [Related]
60. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
